Guidelines for drug useCISMeF resources Type

https://ansm.sante.fr/tableau-acces-derogatoire/zanidatamab
2025
false
false
false
France
French
infusions, intravenous
zanidatamab
drug information
summary of product characteristics
package leaflet
adult
biliary tract neoplasms
HER2 positive biliary tract cancer
HER2/Neu Expression by Immunohistochemistry 3+
zanidatamab
Locally Advanced Bile Duct Carcinoma
Metastatic Bile Duct Carcinoma
Unresectable Bile Duct Carcinoma
guidelines for drug use

---
https://ansm.sante.fr/tableau-marr/pomalidomide
2025
false
false
false
France
French
risk management
pregnancy
contraception
teratogens
abnormalities, drug-induced
multiple myeloma
pomalidomide
continuity of patient care
Drug-Related side effects and adverse reactions
risk factors
guidelines for drug use
thrombocytopenia
neutropenia
blood cell count
thromboembolism
Infections
patient education handout
pregnancy tests
forms
thalidomide
thalidomide

---
https://www.has-sante.fr/jcms/p_3576108/fr/adzynma-apadamtase-alfa-purpura-thrombotique-thrombocytopenique-congenital-pttc-pediatrie
2025
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Apadamtase Alfa
guidelines for drug use
apadamtase alfa and cinaxadamtase alfa
Cinaxadamtase Alfa
enzyme replacement therapy
ADAMTS13 protein, human
injections, intravenous
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
congenital thrombotic thrombocytopenic purpura

---
https://ansm.sante.fr/tableau-marr/thiocolchicoside
2025
false
false
false
France
French
risk management
thiocolchicoside
patient education handout
guidelines for drug use
thiocolchicoside
fetus
Genotoxicity
administration, oral
injections, intramuscular
pregnancy
breast feeding
Male
female
thiocolchicoside
contraception

---
https://ansm.sante.fr/tableau-acces-derogatoire/versatis
2025
false
false
false
France
French
lidocaine
administration, cutaneous
guidelines for drug use
Peripheral neuropathic pain (finding)
neuralgia

---
https://ansm.sante.fr/tableau-acces-derogatoire/nirogacestat
2025
false
false
false
France
French
administration, oral
nirogacestat
ogsiveo
summary of product characteristics
package leaflet
guidelines for drug use
Desmoid Tumors
Refractory Desmoid Fibromatosis
nirogacestat

---
https://ansm.sante.fr/tableau-acces-derogatoire/idhifa
2025
false
false
false
France
French
enasidenib
administration, oral
Product containing only enasidenib in oral dose form (medicinal product form)
technical report
guidelines for drug use
summary of product characteristics

---
https://ansm.sante.fr/tableau-marr/cerliponase-alfa
2025
false
false
false
France
French
guidelines for drug use
risk management
cerliponase alfa
cerliponase alfa
infusions, intracerebroventricular
Movement of device from original site
Device related infection
Device occlusion
infusions, intracerebroventricular

---
https://ansm.sante.fr/tableau-acces-derogatoire/vyjuvek
2025
false
false
false
France
French
insurance, health, reimbursement
Beremagene Geperpavec
beremagene geperpavec
drug information
continuity of patient care
guidelines for drug use
administration, cutaneous
epidermolysis bullosa dystrophica
epidermolysis bullosa dystrophica
infant
child
COL7A1 Gene Mutation
summary of product characteristics
package leaflet
gene therapy

---
https://ansm.sante.fr/actualites/fluoroquinolones-nous-rappelons-limportance-du-bon-usage-de-ces-antibiotiques
2025
false
false
false
France
French
guidelines for drug use
fluoroquinolones
fluoroquinolones
anti-bacterial agents
anti-bacterial agents
administration, oral
injections
fluoroquinolones
Off-Label use
drug interactions
technical report
pharmacovigilance
france
Drug-Related side effects and adverse reactions
ciprofloxacin
levofloxacin
ofloxacin
norfloxacin
Moxifloxacin
lomefloxacin
delafloxacin

---
https://ansm.sante.fr/tableau-acces-derogatoire/tepezza
2025
false
false
false
France
French
summary of product characteristics
guidelines for drug use
insurance, health, reimbursement
tepezza
teprotumumab
teprotumumab
graves ophthalmopathy
graves disease
myxedema
infusions, intravenous

---
https://pgtm.qc.ca/wp-content/uploads/2025/02/re_importance-clinique-des-nmp-et-te-280225.pdf
2025
Canada
guidelines for drug use
Clinical Relevance
drug, nos
private physicians' group office
drug therapy

---
https://ansm.sante.fr/tableau-marr/testosterone-enanthate-de
2025
false
false
false
France
French
risk management
testosterone enanthate
testosterone enanthate
risk
guidelines for drug use
testosterone
injections, intramuscular
Pulmonary oil microembolism (disorder)

---
https://ansm.sante.fr/actualites/contraception-et-risque-de-meningiome-nouvelles-recommandations
2025
false
false
false
France
French
risk management
contraceptives, oral, hormonal
meningioma
patients guideline
guidelines for drug use
continuity of patient care
risk
desogestrel
risk factors
meningioma

---
https://ansm.sante.fr/tableau-marr/etranacogene-dezaparvovec
2025
false
false
false
France
French
risk management
Etranacogene Dezaparvovec
etranacogene dezaparvovec
guidelines for drug use
patients guideline
popular works
thromboembolism
Drug-Related side effects and adverse reactions
Chemical and Drug Induced Liver Injury
gene therapy
Gene Therapy Agents
semen
blood
DNA-Mediated Gene Transfer
pregnancy
gene transfer, horizontal

---
https://ansm.sante.fr/dossiers-thematiques/bon-usage-des-benzodiazepines
2025
false
false
false
France
French
guidelines for drug use
patients guideline
benzodiazepines
directory

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/ketamine-pertinence-dans-la-depression-refractaire-aux-traitements-et-encadrement.html
2025
Canada
guidelines for drug use
depression
depression, nos
depressive disorder
ketamine

---
https://ansm.sante.fr/informations-de-securite/risperidone-1-mg-ml-en-solution-buvable-risperdal-et-generiques-attention-aux-erreurs-medicamenteuses-pouvant-entrainer-un-surdosage-grave-chez-les-enfants-et-les-adolescents
2025
false
false
false
France
French
pharmacovigilance note
medication errors
adolescent
child
risperidone
guidelines for drug use

---
https://ansm.sante.fr/actualites/rifampicine-conduites-a-tenir-dans-un-contexte-de-fortes-tensions-dapprovisionnement
2025
false
false
false
France
French
rifampin
france
administration, oral
infusions, intravenous
guidelines for drug use
antibiotics, antitubercular
-
-
-
osteoarticular infections
tuberculosis
Infection associated with device (disorder)
Infection associated with vascular device (disorder)
Staphylococcal endocarditis (disorder)

---
https://ansm.sante.fr/tableau-acces-derogatoire/namuscla-167-mg-gelule
2025
false
false
false
France
French
drug information
mexiletine
guidelines for drug use
adult
myotonic dystrophy

---
https://ansm.sante.fr/tableau-marr/zilucoplan
2025
false
false
false
France
French
risk management
guidelines for drug use
patients guideline
injections, subcutaneous
zilucoplan
Drug-Related side effects and adverse reactions
zilucoplan
complement inactivating agents
vaccination
meningococcal infections
meningococcal vaccines
guideline

---
https://ansm.sante.fr/tableau-marr/mavacamten
2025
false
false
false
France
French
risk management
mavacamten
mavacamten
mavacamten
administration, oral
patients guideline
guidelines for drug use
fetus
pregnancy
embryo
drug interactions
heart failure, systolic
Fetal exposure to drug (situation)
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors
Cytochrome P450 family 2 subfamily C member 19 intermediate metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 ultra-rapid metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 poor metabolizer (finding)
Cytochrome P450 family 2 subfamily C member 19 normal metabolizer (finding)
patient education handout

---
https://ansm.sante.fr/tableau-acces-derogatoire/avastin-r-25-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
Bevacizumab
drug information
guidelines for drug use
intravitreal injections
macular degeneration
Neovascular age-related macular degeneration

---
https://ansm.sante.fr/tableau-marr/lisocabtagene-maraleucel
2025
false
false
false
France
French
guidelines for drug use
risk management
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
Cytokine Release Syndrome
continuity of patient care
gene therapy
immunotherapy, adoptive
signs and symptoms
nervous system diseases
patients guideline
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-marr/fentanyl-6
2025
false
false
false
France
French
fentanyl
Fentanyl Citrate
risk management
administration, sublingual
guidelines for drug use
fentanyl
patients guideline
adult
breakthrough pain
drug prescriptions
narcotics
Cancer Pain

---
https://ansm.sante.fr/tableau-acces-derogatoire/ursofalk-250-mg-5-ml-suspension-buvable
https://ansm.sante.fr/tableau-acces-derogatoire/ursofalk-250-mg-5-ml-suspension-buvable#
2025
false
false
false
France
French
ursodeoxycholic acid
guidelines for drug use
cystic fibrosis
Hepatobiliary Disorders
administration, oral
infant
child
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2025
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet
antineoplastic combined chemotherapy protocols

---
https://ansm.sante.fr/tableau-marr/eladocagene-exuparvovec
2025
false
false
false
France
French
risk management
guidelines for drug use
Eladocagene Exuparvovec
drug compounding
Stereotactic surgery
stereotaxic techniques
gene therapy
Intraputaminal Route of Administration
aromatic amino acid decarboxylase deficiency
Injection of brain (procedure)
infusions, parenteral
neurosurgical procedures
patient education handout
guideline
eladocagene exuparvovec

---
https://ansm.sante.fr/tableau-marr/idecabtagene-vicleucel
2025
false
false
false
France
French
guidelines for drug use
popular works
risk management
idecabtagene vicleucel
idecabtagene vicleucel
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
drug compounding
idecabtagene vicleucel
gene therapy
immunotherapy, adoptive
idecabtagene vicleucel
continuity of patient care
nervous system diseases
infusions, intravenous
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
Cytokine Release Syndrome
Cytokine Release Syndrome
signs and symptoms
defrosting

---
https://ansm.sante.fr/tableau-acces-derogatoire/jakavi-5-mg-comprime
2025
false
false
false
France
French
insurance, health, reimbursement
ruxolitinib phosphate
ruxolitinib
administration, oral
graft vs host disease
Steroid Refractory Graft Versus Host Disease
acute disease
chronic disease
pharmaceutical solutions
child
guidelines for drug use
summary of product characteristics
package leaflet
tablets

---
https://ansm.sante.fr/tableau-marr/adrenaline
2025
false
false
false
France
French
risk management
guidelines for drug use
epinephrine
epinephrine
Self injection
self administration
patient education handout
video recording

---
https://ansm.sante.fr/tableau-marr/fentanyl-8
2025
false
false
false
France
French
fentanyl
patients guideline
guidelines for drug use
risk management
video recording
guideline
fentanyl

---
https://ansm.sante.fr/tableau-acces-derogatoire/rybrevant
2025
false
false
false
France
French
summary of product characteristics
amivantamab
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
guidelines for drug use
package leaflet
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
EGFR Exon 20 Insertion Mutation

---
https://ansm.sante.fr/tableau-marr/eliglustat
2025
false
false
false
France
French
risk management
eliglustat
guidelines for drug use
drug interactions
popular works
eliglustat
gaucher disease, type 1
Cytochrome P-450 CYP2D6 Inhibitors
P-glycoprotein Inhibitor
Genotyping
continuity of patient care
Metabolic Side Effects of Drugs and Substances

---
https://ansm.sante.fr/tableau-marr/cladribine
2025
false
false
false
France
French
risk management
cladribine
administration, oral
cladribine
immunosuppressive agents
cladribine
guidelines for drug use
patients guideline
Drug-Related side effects and adverse reactions
adult
multiple sclerosis, relapsing-remitting
continuity of patient care
hematologic tests

---
https://ansm.sante.fr/tableau-acces-derogatoire/imcivree#
2025
false
false
false
France
French
setmelanotide
adult
adolescent
child
obesity
obesity
bardet-biedl syndrome
continuity of patient care
drug monitoring
product surveillance, postmarketing
setmelanotide
injections, subcutaneous
guidelines for drug use
package leaflet
summary of product characteristics
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/enhertu-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
Metastatic Gastric Adenocarcinoma
stomach neoplasms
adenocarcinoma
neoplasm metastasis
Locally Advanced Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
HER2/Neu Positive
trastuzumab deruxtecan
infusions, intravenous
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
Metastatic HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm recurrence, local

---
https://ansm.sante.fr/tableau-acces-derogatoire/imfinzi-50-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
durvalumab
guidelines for drug use
Unresectable Biliary Tract Carcinoma
antineoplastic combined chemotherapy protocols
Metastatic Biliary Tract Carcinoma
durvalumab
adult
Cisplatin/Durvalumab/Gemcitabine Regimen
infusions, intravenous
cisplatin
carcinoma, hepatocellular
carcinoma, non-small-cell lung
small cell lung carcinoma
bronchial neoplasms

---
https://ansm.sante.fr/tableau-marr/lauromacrogol-400
2025
false
false
false
France
French
risk management
guidelines for drug use
Polidocanol
polidocanol
patients guideline
Polidocanol
Drug-Related side effects and adverse reactions
continuity of patient care
Polidocanol
drug compounding

---
https://ansm.sante.fr/actualites/amoxicilline-des-recommandations-pour-contribuer-a-garantir-la-couverture-des-besoins-des-patients
2025
false
false
false
France
French
amoxicillin
guidelines for drug use
amoxicillin
administration, oral
infant
child
amoxicillin
amoxicillin-potassium clavulanate combination
amoxicillin-potassium clavulanate combination
amoxicillin and beta-lactamase inhibitor

---
https://ansm.sante.fr/tableau-marr/rivaroxaban
2025
false
false
false
France
French
Rivaroxaban
risk management
guidelines for drug use
continuity of patient care
administration, oral
medication errors
hemorrhage
Drug-Related side effects and adverse reactions
Rivaroxaban
package leaflet
video recording

---
https://ansm.sante.fr/tableau-marr/aflibercept
2025
false
false
false
France
French
guidelines for drug use
patients guideline
aflibercept
recombinant fusion proteins
receptors, vascular endothelial growth factor
Drug-Related side effects and adverse reactions
signs and symptoms
intravitreal injections
video recording
intravitreal injections
sound

---
https://ansm.sante.fr/tableau-marr/methoxyflurane
2025
false
false
false
France
French
risk management
methoxyflurane
administration, inhalation
guidelines for drug use
methoxyflurane
methoxyflurane
Drug-Related side effects and adverse reactions
emergency treatment
pain
wounds and injuries
Post-traumatic pain

---
https://ansm.sante.fr/tableau-marr/adrenaline-3
2025
false
false
false
France
French
risk management
epinephrine
guidelines for drug use
self administration
injections, intramuscular
epinephrine
anaphylaxis
patients guideline
drug storage
video recording
epinephrine

---
https://ansm.sante.fr/tableau-atu-rtu/gymiso-200-microgrammes-comprime-2
2025
false
false
false
France
French
misoprostol
guidelines for drug use
abortion, Drug-Induced
abortifacient agents, nonsteroidal
misoprostol
drug therapy, combination
mifepristone
drug information

---
https://ansm.sante.fr/tableau-acces-derogatoire/lutathera
2025
false
false
false
France
French
infusions, intravenous
drug information
lutetium (177Lu) oxodotreotide
lutetium Lu 177 dotatate
radiopharmaceuticals
guidelines for drug use
Pheochromocytoma-paraganglioma
pheochromocytoma
Metastatic Lung Neuroendocrine Tumor
bronchial neoplasms
neoplasm metastasis
Thymic neuroendocrine tumor
neuroendocrine tumors
thymus neoplasms
Metastatic Thymus Neuroendocrine Neoplasm
meningioma
Somatostatin Receptor Positive
Somatostatin Receptor 2 Positive
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/kaftrio-75-mg-50-mg-100-mg-comprime-pellicule-kalydeco-150-mg-comprime-pellicule
2025
false
false
false
France
French
cystic fibrosis
guidelines for drug use
continuity of patient care
drug therapy, combination
administration, oral
ivacaftor, tezacaftor and elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
elexacaftor
adult
adolescent
ivacaftor
trikafta
drug combinations
drug information

---
https://ansm.sante.fr/tableau-acces-derogatoire/thalidomide-bms-50-mg-gelule
2025
false
false
false
France
French
guidelines for drug use
continuity of patient care
thalidomide
administration, oral
Jessner lymphocytic infiltration of the skin
lupus erythematosus, cutaneous
stomatitis, aphthous
Immune complex reaction co-occurrent and due to multibacillary leprosy (disorder)
crohn disease
erythema multiforme
Erythema multiforme major
technical report

---
https://ansm.sante.fr/tableau-marr/fentanyl-3
2025
false
false
false
France
French
fentanyl
analgesics, opioid
risk management
narcotics
guidelines for drug use
patients guideline
administration, intranasal
nasal sprays
fentanyl
patient education handout

---
https://ansm.sante.fr/tableau-marr/fentanyl-5
2025
false
false
false
France
French
administration, sublingual
fentanyl
analgesics, opioid
risk management
narcotics
guidelines for drug use
patients guideline
fentanyl
Sublingual Tablet Dosage Form

---
https://ansm.sante.fr/tableau-marr/alpelisib
2025
false
false
false
France
French
guidelines for drug use
administration, oral
Drug-Related side effects and adverse reactions
alpelisib
Alpelisib
Alpelisib
continuity of patient care
Hyperglycaemic hyperosmolar nonketotic syndrome
hyperglycemia
ketosis
thiazoles
thiazoles

---
https://ansm.sante.fr/tableau-marr/esketamine
2025
false
false
false
France
French
guidelines for drug use
patients guideline
patient education handout
Esketamine
ketamine
dissociative disorders
administration, intranasal
antidepressive agents
risk management
esketamine
Esketamine
antidepressive agents
continuity of patient care
dissociation
Sleepiness
hypertension
Drug Misuse
ketamine

---
https://ansm.sante.fr/tableau-marr/fingolimod
2025
false
false
false
France
French
guidelines for drug use
patient education handout
Fingolimod Hydrochloride
pregnancy
administration, oral
immunosuppressive agents
immunosuppressive agents
fingolimod
continuity of patient care
Fingolimod Hydrochloride
teratogens
multiple sclerosis, relapsing-remitting
breast feeding
Fingolimod Hydrochloride
risk management

---
https://ansm.sante.fr/tableau-acces-derogatoire/opdivo-nivolumab-solution-a-diluer-pour-perfusion-yervoy-ipilimumab-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
Malignant Pleural Mesothelioma
disease progression
Progressive Neoplastic Disease
infusions, intravenous
continuity of patient care
drug monitoring
carcinoma, non-small-cell lung
melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIIB Cutaneous Melanoma AJCC v7
technical report

---
https://ansm.sante.fr/tableau-marr/levodopa-carbidopa
2025
false
false
false
France
French
risk management
carbidopa
levodopa
drug combinations
carbidopa, levodopa drug combination
Intestinal Route of Administration
patient care
nursing care
patient care planning
guidelines for drug use
patient education handout
continuity of patient care
patient care management

---
https://ansm.sante.fr/tableau-marr/icodextrine
2025
false
false
false
France
French
risk management
guidelines for drug use
peritoneal dialysis
blood glucose self-monitoring
Icodextrin
Blood glucose meter (physical object)
directory
patient education handout

---
https://ansm.sante.fr/tableau-acces-derogatoire/arikayce-liposomal
2025
false
false
false
France
French
guidelines for drug use
mycobacterium infections, nontuberculous
amikacin
liposomes
administration, inhalation
pneumonia, bacterial
anti-bacterial agents
Mycobacterium abscessus
amikacin
Infection caused by Mycobacteroides abscessus (disorder)

---
https://ansm.sante.fr/tableau-acces-derogatoire/venclyxto-10-mg-50mg-100-mg-comprimes-pellicules?#
2025
false
false
false
France
French
venetoclax
venetoclax
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
leukemia, myeloid, acute
precursor cell lymphoblastic Leukemia-Lymphoma
Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
leukemia, lymphocytic, chronic, B-Cell
drug information
Product containing only venetoclax in oral dose form (medicinal product form)
guidelines for drug use
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic

---
https://ansm.sante.fr/tableau-acces-derogatoire/slenyto
2025
false
false
false
France
French
guidelines for drug use
melatonin
administration, oral
Delayed-Action preparations
child
adolescent
sleep disorders, circadian rhythm
melatonin
rett syndrome
angelman syndrome
tuberous sclerosis
technical report

---
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy

---
https://www.inesss.qc.ca/covid-19/autres-traitements/utilisation-des-antiviraux-pour-le-traitement-et-la-prophylaxie-de-linfluenza-chez-lenfant-et-ladulte-dans-le-contexte-de-la-covid-19.html
2025
false
false
false
Canada
coronavirus infections
pneumonia, viral
influenza, human
aged
influenza, human
risk factors
oseltamivir
zanamivir
continuity of patient care
practice guideline
guidelines for drug use
influenza, human
child
antiviral agents
adult
pandemics
COVID-19

---
https://ansm.sante.fr/tableau-acces-derogatoire/ospolot#
2025
false
false
false
France
French
guidelines for drug use
administration, oral
sulthiame
anticonvulsants
Continuous spikes and waves during sleep
continuity of patient care
sultiame
child
adolescent
adult
ospolot
epilepsy, rolandic
landau-kleffner syndrome
technical report
thiazines

---
https://ansm.sante.fr/tableau-marr/sel-de-fer-injectable
2025
false
false
false
France
French
risk management
iron compounds
iron, parenteral preparations
patient education handout
guidelines for drug use
injections, intravenous
infusions, intravenous
iron compounds
anaphylaxis
drug hypersensitivity
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-acces-derogatoire/ciclograft-20mg-ml-collyre-en-solution-en-recipient-unidose
2024
false
false
false
false
France
French
package leaflet
cyclosporine
administration, ophthalmic
guidelines for drug use
corneal transplantation
graft rejection
summary of product characteristics

---
https://ansm.sante.fr/tableau-marr/fenfluramine
2024
false
false
false
France
French
administration, oral
risk management
guidelines for drug use
pharmacovigilance note
fenfluramine
fenfluramine
continuity of patient care
drug monitoring
hypertension, pulmonary
Drug-Related side effects and adverse reactions
heart valve diseases
patients guideline
Off-Label use

---
https://ansm.sante.fr/tableau-marr/romiplostim
2024
false
false
false
France
French
injections, subcutaneous
romiplostim
risk management
romiplostim
guidelines for drug use
child
adult
patients guideline
clinical tool
home nursing
drug dosage calculations
self administration
receptors, fc
recombinant fusion proteins
thrombopoietin

---
https://ansm.sante.fr/tableau-atu-rtu/gavreto-100-mg-gelule
2024
false
false
false
France
French
pralsetinib
antineoplastic agents
guidelines for drug use
pralsetinib
pyrazoles
pyridines
pyrimidines

---
https://ansm.sante.fr/tableau-marr/tolvaptan
2024
false
false
false
France
French
risk management
Tolvaptan
Tolvaptan
administration, oral
tolvaptan
polycystic kidney, autosomal dominant
continuity of patient care
liver diseases
pregnancy
guidelines for drug use
patients guideline
patient education handout

---
https://ansm.sante.fr/tableau-marr/olanzapine
2024
false
false
false
France
French
guidelines for drug use
patient education handout
Olanzapine
risk management
olanzapine
injections, intramuscular
Delayed-Action preparations
Olanzapine
metabolic diseases
continuity of patient care
drug compounding
injections, intramuscular
olanzapine pamoate
olanzapine pamoate
schizophrenia
antipsychotic agents
antipsychotic agents
medication errors
Post-injection delirium sedation syndrome (finding)

---
https://ansm.sante.fr/tableau-marr/eculizumab
2024
false
false
false
France
French
risk management
guidelines for drug use
eculizumab
eculizumab
continuity of patient care
drug monitoring
patient safety
sepsis
meningococcal infections
risk
vaccination
antibiotic prophylaxis
adult
child
infant
patients guideline
patient education handout
Drug-Related side effects and adverse reactions
meningococcal vaccines

---
https://ansm.sante.fr/tableau-atu-rtu/mylotarg-5-mg-poudre-pour-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
Gemtuzumab
gemtuzumab ozogamicin
guidelines for drug use
continuity of patient care
drug monitoring
leukemia, myeloid, acute
adult
child
recurrence
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
CD33 Positive
antineoplastic combined chemotherapy protocols
infusions, intravenous
Antineoplastic Agents, Immunological
gemtuzumab ozogamicin
technical report

---
https://ansm.sante.fr/tableau-marr/etonogestrel
2024
false
false
false
France
French
risk management
guidelines for drug use
patients guideline
patient education handout
etonogestrel
drug implants
Insertion of etonogestrel radiopaque contraceptive implant (procedure)
Removal of etonogestrel radiopaque contraceptive implant (procedure)
Insertion of subcutaneous contraceptive in arm (procedure)
etonogestrel
contraceptive agents, female
progestins

---
2024
false
false
false
France
French
osimertinib
summary of product characteristics
package leaflet
guidelines for drug use
administration, oral
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
bronchial neoplasms
bronchial neoplasms
EGF Receptors
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
osimertinib
EGFR NP_005219.2:p.L858R
EGFR Exon 19 Deletion Mutation
ErbB Receptors
acrylamides
aniline compounds

---
https://www.omedit-centre.fr/medias/Tramadol.pdf
2024
true
France
French
tramadol
tramadol
drug interactions
aged
tramadol
pregnancy
tramadol
analgesics, opioid
tramadol
guidelines for drug use
Contraindications, Drug

---
https://www.omedit-centre.fr/medias/Codeine-dihydrocodeine_Adulte.pdf
2024
false
false
false
France
French
pain
analgesics, opioid
administration, oral
guidelines for drug use
adult
dihydrocodeine
codeine
codeine

---
https://www.omedit-centre.fr/medias/Reconstitution-administration_antiinfectieux-injectables.pdf
2024
false
false
false
France
French
guidelines for drug use
drug compounding
injections, intramuscular
anti-bacterial agents
drug stability
injections, subcutaneous
injections, intravenous
drug compounding
Administration of antibiotic (procedure)
Infusion Pumps
infusion pumps, implantable
infusions, parenteral
antibacterials for systemic use
ambulatory care

---
https://ansm.sante.fr/tableau-atu-rtu/kymriah-1-2-x-106-6-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
tisagenlecleucel
tisagenlecleucel
lymphoma, follicular
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
tisagenlecleucel
risk management
infusions, intravenous
antineoplastic agents
antineoplastic agents
patients guideline

---
https://ansm.sante.fr/tableau-marr/acitretine
2024
false
false
false
France
French
guidelines for drug use
patients guideline
risk management
teratogens
continuity of patient care
acitretin
acitretin
pregnancy
contraception
administration, oral
acitretin
mental disorders
drug monitoring
Chemical and Drug Induced Liver Injury
pancreatitis
psoriasis
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-marr/alitretinoine
2024
false
false
false
France
French
guidelines for drug use
patients guideline
forms
administration, oral
teratogens
pregnancy
contraception
alitretinoin
mental disorders
dyslipidemias
continuity of patient care
pancreatitis
transaminases
Chemical and Drug Induced Liver Injury
drug monitoring
risk management
clinical chemistry tests
patient education handout
Drug-Related side effects and adverse reactions
Alitretinoin
Alitretinoin

---
https://ansm.sante.fr/tableau-marr/emicizumab
2024
false
false
false
France
French
emicizumab
risk management
thromboembolism
hemorrhage
thrombotic microangiopathies
blood coagulation tests
risk
hemorrhage
hemophilia A
patients guideline
guidelines for drug use
handbooks
Drug-Related side effects and adverse reactions
injections, subcutaneous
emicizumab
emicizumab
continuity of patient care
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://ansm.sante.fr/tableau-marr/insuline-degludec
2024
false
false
false
France
French
risk management
insulin degludec
medication errors
guidelines for drug use
injections, subcutaneous
insulin degludec
patient education handout
hypoglycemic agents
guideline
insulin, long-acting

---
https://ansm.sante.fr/tableau-marr/insuline-glargine
2024
false
false
false
France
French
Insulin Glargine
medication errors
risk management
insulin glargine
guidelines for drug use
patients guideline

---
https://ansm.sante.fr/tableau-marr/isotretinoine
2024
false
false
false
France
French
administration, oral
isotretinoin
risk management
acne vulgaris
isotretinoin
teratogens
pregnancy
contraception
mental disorders
dyslipidemias
Chemical and Drug Induced Liver Injury
patient education handout
forms
pancreatitis
guidelines for drug use
continuity of patient care
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-marr/lenalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
lenalidomide
multiple myeloma
lymphoma, mantle-cell
teratogens
continuity of patient care
drug monitoring
clinical chemistry tests
myelodysplastic syndromes
guidelines for drug use
popular works
venous thromboembolism
Tumor Flare Reaction
neoplasms
Chemical and Drug Induced Liver Injury
angiogenesis inhibitors
angiogenesis inhibitors
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide

---
https://ansm.sante.fr/tableau-marr/sonidegib
2024
false
false
false
France
French
risk management
sonidegib
teratogens
pregnancy
abnormalities, drug-induced
contraception
pregnancy tests
antineoplastic agents
fetal death
patient education handout
guidelines for drug use
guideline
sonidegib
biphenyl compounds
pyridines

---
https://ansm.sante.fr/tableau-marr/vandetanib
2024
false
false
false
France
French
risk management
vandetanib
vandetanib
Cardiotoxicity
adult
child
posterior leukoencephalopathy syndrome
death, sudden
long qt syndrome
torsades de pointes
continuity of patient care
drug monitoring
drug interactions
medication errors
vandetanib
handbooks
popular works
RET Gene Mutation
guidelines for drug use
piperidines
quinazolines
piperidines
quinazolines

---
https://ansm.sante.fr/tableau-marr/pirfenidone
2024
false
false
false
France
French
guidelines for drug use
risk management
pirfenidone
pirfenidone
administration, oral
patient education handout
photosensitization
Drug-induced photosensitivity (disorder)
pirfenidone
Chemical and Drug Induced Liver Injury
continuity of patient care
liver function tests
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-marr/eculizumab-2
2024
false
false
false
France
French
risk management
eculizumab
eculizumab
eculizumab
guidelines for drug use
patient education handout
patients guideline
antibiotic prophylaxis
infusions, intravenous
Infections
sepsis
Drug-Related side effects and adverse reactions
meningococcal infections
vaccination
meningococcal vaccines

---
https://ansm.sante.fr/tableau-acces-derogatoire/concizumab
2024
false
false
false
France
French
concizumab
guidelines for drug use
summary of product characteristics
package leaflet
technical report
hemophilia A
hemophilia B
hemorrhage
adolescent

---
https://ansm.sante.fr/tableau-acces-derogatoire/dabrafenib
2024
false
false
false
France
French
dabrafenib
drug information
guidelines for drug use
administration, oral
summary of product characteristics
package leaflet
Disintegrating Tablet Dosage Form
glioma
dabrafenib
child
BRAF Inhibitor
infant

---
https://ansm.sante.fr/tableau-acces-derogatoire/trametinib
2024
false
false
false
France
French
summary of product characteristics
package leaflet
administration, oral
Powder for Oral Solution Dosage Form
child
guidelines for drug use
trametinib
trametinib
drug information
glioma
BRAF Inhibitor

---
https://ansm.sante.fr/actualites/fibrinogene-humain-lansm-a-elabore-un-guide-pratique-pour-favoriser-le-bon-usage-des-produits-disponibles
2024
false
false
false
France
French
drug compounding
drug storage
guidelines for drug use
fibrinogen
human fibrinogen
Fibrinogen Human
Product containing only human fibrinogen (medicinal product)
fibrinogen

---
https://ansm.sante.fr/tableau-acces-derogatoire/inspra-25-mg-comprime-pellicule
2024
false
false
false
France
French
Eplerenone
continuity of patient care
guidelines for drug use
adult
hyperaldosteronism
technical report

---
https://ansm.sante.fr/actualites/renforcer-linformation-des-professionnels-de-sante-pour-une-utilisation-securisee-du-chlorure-de-potassium-kcl-injectable
2024
false
false
false
France
French
guidelines for drug use
training
potassium chloride
patient safety
potassium chloride
Serious Adverse Drug Reaction
infusions, intravenous
medication errors

---
https://ansm.sante.fr/tableau-marr/inhibiteur-de-la-c1-esterase-humaine
2024
false
false
false
France
French
risk management
guidelines for drug use
continuity of patient care
Human C1-Esterase Inhibitor
patients guideline

---
https://publications.msss.gouv.qc.ca/msss/document-003676/
2024
Canada
guidelines for drug use
Transference
Ambulatory Care Facility
Usage
Clinical Data
Countertransference
Transfer, Psychology
Healthcare Activity
Intervention for Congenital Heart Disease
Clinical Batch
clinical protocols
Healthcare
Clinical Lot
Transfer
nursing
Care
On Study
Clinical Study Protocol
How True Feel Carefree Right Now
Intervention
Transfer Ability
Stooping

---
https://ansm.sante.fr/tableau-marr/susoctocog-alfa
2024
false
false
false
France
French
risk management
Susoctocog Alfa
medication errors
guidelines for drug use
drug dosage calculations
video recording

---
https://ansm.sante.fr/tableau-marr/mecasermine
2024
false
false
false
France
French
risk management
mecasermin
mecasermin
mecasermin
Drug-Related side effects and adverse reactions
patient education handout
guidelines for drug use
mecasermin
hypoglycemia
injections, subcutaneous

---
https://ansm.sante.fr/tableau-acces-derogatoire/itraconazole
2024
false
false
false
France
French
itraconazole
guidelines for drug use
administration, oral
tinea
child
microsporum
antifungal agents
itraconazole
continuity of patient care

---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib

---
https://ansm.sante.fr/tableau-marr/methotrexate-per-os
2024
false
false
false
France
French
guidelines for drug use
risk management
methotrexate
administration, oral
patient education handout
medication errors

---
https://www.has-sante.fr/jcms/p_3495394/fr/takhzyro-lanadelumab-angioedeme-hereditaire
2024
false
false
false
France
French
insurance, health, reimbursement
lanadelumab
evaluation of the transparency committee
child
angioedemas, hereditary
Hereditary angioedema attack
lanadelumab
treatment outcome
guidelines for drug use
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug)

---
https://www.has-sante.fr/jcms/p_3473151/fr/fiche-bum-dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2024
false
false
false
France
dupilumab
benralizumab
mepolizumab
tezepelumab
other systemic drugs for obstructive airway diseases
adult
child
drug therapy, combination
Severe persistent asthma (disorder)
adolescent
Respiratory corticosteroid (substance)
adrenergic beta-2 receptor agonists
guidelines for drug use
Omalizumab
asthma

---
https://www.has-sante.fr/jcms/p_3468175/fr/imfinzi-durvalumab-cancer-des-voies-biliaires
2024
false
false
false
France
Cisplatin/Durvalumab/Gemcitabine Regimen
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
cisplatin
Gemcitabine
Unresectable Biliary Tract Carcinoma
Metastatic Biliary Tract Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
durvalumab
adult
guidelines for drug use
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
durvalumab

---
https://ansm.sante.fr/tableau-marr/tocilizumab-1
2024
false
false
false
France
French
risk management
tocilizumab
infusions, intravenous
injections, subcutaneous
guidelines for drug use
tocilizumab
tocilizumab
patient education handout
continuity of patient care
tocilizumab

---
https://ansm.sante.fr/tableau-marr/tafamidis
2024
false
false
false
France
French
risk management
tafamidis
administration, oral
guidelines for drug use
tafamidis
adult
pregnancy
breast feeding
tafamidis
Cardiac Amyloidosis
amyloidosis, hereditary, Transthyretin-Related
amyloidosis, hereditary, Transthyretin-Related

---
https://ansm.sante.fr/informations-de-securite/paxlovid-nirmatrelvir-ritonavir-rappel-des-interactions-medicamenteuses-avec-certains-immunosuppresseurs-notamment-le-tacrolimus-pouvant-etre-fatales
2024
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
drug interactions
nirmatrelvir and ritonavir drug combination
nirmatrelvir
immunosuppressive agents
tacrolimus
COVID-19 Drug Treatment
adult
nirmatrelvir and ritonavir
tacrolimus

---
https://www.has-sante.fr/jcms/p_3503277/fr/evkeeza-evinacumab-hypercholesterolemie-homozygote-familiale
2024
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Homozygous Familial Hypercholesterolemia
antibodies, monoclonal
evinacumab
guidelines for drug use
package leaflet
summary of product characteristics
Product containing only evinacumab in parenteral dose form (medicinal product form)
infusions, intravenous
evaluation of the transparency committee
evkeeza
evinacumab

---
https://www.has-sante.fr/jcms/p_3503249/fr/elrexfio-elranatamab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antibodies, monoclonal
adult
multiple myeloma
package leaflet
summary of product characteristics
guidelines for drug use
recurrence
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
Progressive Neoplastic Disease
relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy
elranatamab
evaluation of the transparency committee
Elranatamab

---
https://www.has-sante.fr/jcms/p_3505636/fr/rybrevant-amivantamab-cancer-bronchique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
carboplatin
amivantamab
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
EGFR Exon 20 Insertion Mutation
Pemetrexed
adult
package leaflet
summary of product characteristics
guidelines for drug use
infusions, intravenous
evaluation of the transparency committee
bronchial neoplasms
amivantamab

---
https://www.has-sante.fr/jcms/p_3505761/fr/retsevmo-selpercatinib-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
bronchial neoplasms
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
administration, oral
selpercatinib
package leaflet
summary of product characteristics
guidelines for drug use
advanced RET fusion-positive non-small cell lung cancer
RET Fusion Positive
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
evaluation of the transparency committee
selpercatinib
carcinoma, non-small-cell lung

---
https://www.cbip.be/fr/elderlymeds
2024
false
false
false
Belgium
French
Dutch
aged
pharmaceutical preparations
drug prescriptions
guidelines for drug use

---
https://ansm.sante.fr/tableau-marr/belatacept
2024
false
false
false
France
French
guidelines for drug use
risk management
BELATACEPT
immunosuppressive agents
infusions, intravenous
belatacept
patient education handout
Infusion-Related Reaction
infusions, intravenous

---
https://ansm.sante.fr/tableau-marr/sutimlimab
2024
false
false
false
France
French
risk management
sutimlimab
guidelines for drug use
sutimlimab
antibodies, monoclonal, humanized
infusions, intravenous
Infections
Infections
meningococcal vaccines
meningococcal infections
vaccination
serious infection
patient education handout

---
https://ansm.sante.fr/tableau-marr/glucagon
2024
false
false
false
France
French
guidelines for drug use
risk management
glucagon
glucagon
administration, intranasal
patient education handout

---
https://ansm.sante.fr/tableau-marr/ritlecitinib
2024
false
false
false
France
French
risk management
Ritlecitinib
Drug-Related side effects and adverse reactions
ritlecitinib
guidelines for drug use
patient education handout
administration, oral
Janus Kinase Inhibitors
Immunomodulating Agents

---
https://ansm.sante.fr/tableau-marr/dronedarone
2024
false
false
false
France
French
risk management
continuity of patient care
Dronedarone
Dronedarone
dronedarone
administration, oral
guidelines for drug use
patient education handout
atrial fibrillation
Persistent Atrial Fibrillation
Paroxysmal Atrial Fibrillation
anti-arrhythmia agents
anti-arrhythmia agents

---
https://www.cbip.be/fr/articles/4309?folia=4305
2024
false
false
false
Belgium
French
Dutch
journal article
belgium
pulmonary disease, chronic obstructive
patients guideline
guidelines for drug use

---
https://www.has-sante.fr/jcms/p_3508311/fr/sotatercept-sotatercept-hypertension-arterielle-pulmonaire
2024
false
false
false
France
ACE-011
adult
drug therapy, combination
Pulmonary arterial hypertension WHO functional class II
Pulmonary arterial hypertension WHO functional class III
guidelines for drug use
orphan drug production
sotatercept
evaluation of the transparency committee
Pulmonary Arterial Hypertension
sotatercept

---
https://ansm.sante.fr/actualites/nulojix-belatacept-pour-la-greffe-de-rein-recommandations-temporaires-pour-garantir-la-continuite-des-soins
2024
false
false
false
France
French
guidelines for drug use
Abatacept

---
https://ansm.sante.fr/tableau-marr/fosphenytoine-sodique
2024
false
false
false
France
French
risk management
fosphenytoin
fosphenytoin sodium
guidelines for drug use
child
adult
injections, intramuscular
infusions, intravenous
anticonvulsants
fosphenytoin
medication errors
emergency treatment
status epilepticus

---
https://ansm.sante.fr/tableau-marr/dabigatran
2024
false
false
false
France
French
guidelines for drug use
risk management
Dabigatran
Dabigatran
dabigatran etexilate
administration, oral
antithrombins
antithrombins
continuity of patient care
hemorrhage
risk
adult
child

---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma

---
https://www.has-sante.fr/jcms/p_3418585/fr/yescarta-axicabtagene-ciloleucel-lymphome-ldgcb-lhgcb
2024
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
infusions, intravenous
gene therapy
axicabtagene ciloleucel

---
https://ansm.sante.fr/tableau-marr/rituximab-3
2024
false
false
false
France
French
guidelines for drug use
patient education handout
Rituximab
Rituximab
risk management
continuity of patient care
child
infusions, intravenous
leukoencephalopathy, progressive multifocal
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-acces-derogatoire/niraparib-acetate-dabiraterone
2024
false
false
false
France
French
summary of product characteristics
package leaflet
drug combinations
administration, oral
Abiraterone Acetate/Niraparib
Abiraterone Acetate
niraparib
antineoplastic agents
guidelines for drug use
antineoplastic combined chemotherapy protocols
metastatic castration resistant prostate cancer
prostatic neoplasms, Castration-Resistant
niraparib and abiraterone

---
https://ansm.sante.fr/tableau-marr/ravulizumab
2024
false
false
false
France
French
risk management
ravulizumab
ravulizumab
ravulizumab
infusions, intravenous
guidelines for drug use
patients guideline
continuity of patient care
meningococcal infections
sepsis
neisseria meningitidis
vaccination
antibiotic prophylaxis
meningococcal infections
sepsis
child
infant
hemoglobinuria, paroxysmal
Atypical Hemolytic Uremic Syndrome
myasthenia gravis, generalized

---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab

---
https://ansm.sante.fr/tableau-acces-derogatoire/alpelisib-200-mg-comprimes-pellicules
2024
false
false
false
France
French
Alpelisib
administration, oral
drug information
guidelines for drug use
congenital lipomatous overgrowth, vascular malformations, and epidermal nevi
PIK3CA-related overgrowth syndrome
PIK3CA-Related Overgrowth Spectrum
Phosphatidylinositide 3-Kinase Inhibitor
summary of product characteristics
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/mabthera-100-mg-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
infusions, intravenous
Product containing precisely rituximab 10 milligram/1 milliliter conventional release solution for infusion (clinical drug)
Rituximab
drug information
guidelines for drug use
Refractory immune thrombocytopenic purpura
purpura, thrombocytopenic, idiopathic
immunologic factors
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/methotrexate
2024
false
false
false
France
French
methotrexate
guidelines for drug use
pregnancy, ectopic
administration, oral
pharmaceutical solutions
injections
arthritis, juvenile
uveitis, anterior
drug information
precursor cell lymphoblastic Leukemia-Lymphoma

---
https://ansm.sante.fr/tableau-marr/axicabtagene-ciloleucel
2024
false
false
false
France
French
risk management
axicabtagene ciloleucel
guidelines for drug use
axicabtagene ciloleucel
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
nervous system diseases
patient education handout
signs and symptoms
axicabtagene ciloleucel
infusions, intravenous
gene therapy

---
https://ansm.sante.fr/tableau-marr/brexucabtagene-autoleucel
2024
false
false
false
France
French
risk management
brexucabtagene autoleucel
genetic therapy
gene therapy
Cytokine Release Syndrome
signs and symptoms
guidelines for drug use
patient education handout
Drug-Related side effects and adverse reactions
nervous system diseases
brexucabtagene autoleucel
brexucabtagene autoleucel

---
https://ansm.sante.fr/tableau-marr/tacrolimus
2024
false
false
false
France
French
risk management
tacrolimus
tacrolimus
administration, oral
guidelines for drug use
patient education handout
continuity of patient care
immunosuppressive agents

---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2024
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive

---
https://ansm.sante.fr/tableau-acces-derogatoire/dupixent
2024
false
false
false
France
French
summary of product characteristics
package leaflet
injections, subcutaneous
dupilumab
adult
Prurigo nodularis (disorder)
guidelines for drug use
prurigo
dupilumab
dermatitis, atopic
child

---
https://ansm.sante.fr/tableau-marr/leflunomide
2024
false
false
false
France
French
risk management
patients guideline
guidelines for drug use
Leflunomide
leflunomide
administration, oral
immunosuppressive agents
continuity of patient care
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-acces-derogatoire/breyanzi
2024
false
false
false
France
French
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
summary of product characteristics
package leaflet
guidelines for drug use
lymphoma, large B-Cell, diffuse
adult
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
continuity of patient care
immunotherapy, adoptive
antigens, CD19
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/berinert-500-ui-mg-poudre-et-solvant-pour-solution-injectable-perfusion
2024
false
false
false
France
French
complement C1 inhibitor protein
guidelines for drug use
continuity of patient care
salvage therapy
graft rejection
Humoral rejection
heart transplantation
kidney transplantation
lung transplantation
infusions, intravenous
complement C1 inhibitor protein
technical report

---
https://ansm.sante.fr/tableau-marr/tetradecyl-sulfate-de-sodium
2024
false
false
false
France
French
risk management
guidelines for drug use
continuity of patient care
sodium tetradecyl sulfate
sclerosing solutions
sodium tetradecyl sulfate
sodium tetradecyl sulfate
injections, intravenous
sclerotherapy
drug prescriptions

---
https://ansm.sante.fr/tableau-marr/selexipag
2024
false
false
false
France
French
risk management
Uptravi
medication errors
selexipag
patients guideline
guidelines for drug use
Wrong dose
selexipag

---
https://www.has-sante.fr/jcms/p_3390379/fr/ciclograft-ciclosporine-greffe-de-cornee
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
graft rejection
drug therapy, combination
risk factors
guidelines for drug use
ophthalmic solutions
administration, ophthalmic
immunosuppressive agents
evaluation of the transparency committee
corneal transplantation
cyclosporine

---
https://ansm.sante.fr/tableau-marr/olipudase-alfa
2024
false
false
false
France
French
guidelines for drug use
popular works
risk management
olipudase alfa
olipudase alfa
Drug-Related side effects and adverse reactions
infusions, intravenous
home infusion therapy
Infusion-Related Reaction
drug hypersensitivity
anaphylaxis
olipudase alfa

---
https://ansm.sante.fr/dossiers-thematiques/prevenir-les-erreurs-avec-le-chlorure-de-potassium-injectable
2024
false
false
false
France
French
guidelines for drug use
medication errors
potassium chloride
infusions, intravenous
drug compounding
drug storage
drug prescriptions

---
https://ansm.sante.fr/tableau-marr/oxybate-de-sodium
2024
false
false
false
France
French
guidelines for drug use
risk management
sodium oxybate
administration, oral
continuity of patient care
drug monitoring
adult
adolescent
child
patient education handout
forms
narcolepsy
sodium oxybate
sodium oxybate

---
https://ansm.sante.fr/tableau-marr/capsaicine
2024
false
false
false
France
French
risk management
guidelines for drug use
capsaicin
administration, cutaneous
continuity of patient care
capsaicin

---
https://ansm.sante.fr/tableau-marr/nalmefene
2024
false
false
false
France
French
risk management
nalmefene
nalmefene
guidelines for drug use
patient education handout
administration, oral
patient compliance
patients guideline
alcohol drinking
continuity of patient care
nalmefene
alcoholism
adult
algorithms
Psychosocial Intervention

---
https://ansm.sante.fr/tableau-marr/onasemnogene-abeparvovec
2024
false
false
false
France
French
guidelines for drug use
risk management
Zolgensma
onasemnogene abeparvovec
infusions, intravenous
patients guideline
child
spinal muscular atrophies of childhood
onasemnogene abeparvovec-xioi
biological products
recombinant fusion proteins

---
https://ansm.sante.fr/tableau-atu-rtu/wegovy-solution-injectable-en-stylo-prerempli
2024
false
false
false
France
French
drug information
semaglutide
adult
obesity
weight loss
body mass index
risk factors
comorbidity
summary of product characteristics
package leaflet
guidelines for drug use
patients guideline
continuity of patient care
pregnancy
injections, subcutaneous

---
https://ansm.sante.fr/tableau-marr/ponesimod
2024
false
false
false
France
French
risk management
ponesimod
ponesimod
administration, oral
ponesimod
ponvory
guidelines for drug use
patients guideline
pregnancy
continuity of patient care
ponesimod
adult
multiple sclerosis, relapsing-remitting
drug monitoring
immunosuppressive agents
immunosuppressive agents
immunosuppressive agents

---
https://ansm.sante.fr/tableau-marr/maralixibat
2024
false
false
false
France
French
risk management
maralixibat
maralixibat chloride
guidelines for drug use
patient education handout
medication errors

---
https://ansm.sante.fr/tableau-marr/agalsidase-alpha
2024
false
false
false
France
French
risk management
agalsidase alfa
agalsidase alfa
infusions, intravenous
guidelines for drug use
patients guideline
continuity of patient care
drug hypersensitivity
self administration

---
https://ansm.sante.fr/tableau-marr/laronidase
2024
false
false
false
France
French
risk management
Laronidase
infusions, intravenous
drug hypersensitivity
home nursing
guidelines for drug use
patients guideline
laronidase
home infusion therapy
Infusion-Related Reaction

---
https://www.omedit-centre.fr/medias/Adaptation-posologie-antibiotiques_Adulte-obese.pdf
2024
false
France
French
anti-bacterial agents
adult
obesity
overweight
body mass index
guidelines for drug use
antibiotic therapy
narrow therapeutic range drugs

---
https://ansm.sante.fr/actualites/modification-des-conditions-de-prescription-et-de-delivrance-de-certaines-biotherapies-utilisees-dans-le-traitement-de-maladies-inflammatoires-chroniques
2024
false
false
false
France
French
guidelines for drug use
injections, subcutaneous
Interleukin Inhibitors
immunosuppressive agents
biological therapy
general practice
antibodies, monoclonal
immunoconjugates
Tumor Necrosis Factor Inhibitors
Chronic inflammatory disorder (disorder)

---
https://ansm.sante.fr/tableau-marr/darvadstrocel
2024
false
false
false
France
French
risk management
Darvadstrocel
darvadstrocel
guidelines for drug use
guideline
medication errors
Darvadstrocel
drug storage
Infections
cold chain
temperature recording

---
https://ansm.sante.fr/tableau-marr/natalizumab-1
2024
false
false
false
France
French
Natalizumab
risk management
Natalizumab
natalizumab
guidelines for drug use
patient education handout
continuity of patient care
Drug-Related side effects and adverse reactions
opportunistic infections
leukoencephalopathy, progressive multifocal
immunologic factors
immunologic factors
multiple sclerosis

---
https://ansm.sante.fr/tableau-acces-derogatoire/botox
2024
false
false
false
France
French
guidelines for drug use
botulinum toxins, type A
neuralgia
chronic disease
adult
Chronic peripheral neuropathic pain (finding)

---
https://www.has-sante.fr/jcms/p_3515581/fr/finlee-spexotras-dabrafenib-trametinib-gliome-pediatrie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
dabrafenib
protein kinase inhibitors
antineoplastic agents
child
infant
Childhood Low Grade Glioma
malignant glioma
Childhood Malignant Glioma
BRAF V600E Mutation Present
guidelines for drug use
package leaflet
summary of product characteristics
Trametinib Dimethyl Sulfoxide
administration, oral
trametinib
evaluation of the transparency committee
dabrafenib
Dabrafenib/Trametinib Regimen
glioma
trametinib

---
https://www.has-sante.fr/jcms/p_3516966/fr/loargys-pegzilarginase-deficit-en-arginase-1
2024
false
false
false
France
ARG1 protein, human
insurance, health, reimbursement
treatment outcome
orphan drug production
package leaflet
summary of product characteristics
adult
pegzilarginase
adolescent
child
guidelines for drug use
enzyme replacement therapy
continuity of patient care
evaluation of the transparency committee
hyperargininemia
Arginase-1
Pegzilarginase

---
https://www.has-sante.fr/jcms/p_3517015/fr/fabhalta-iptacopan-hemoglobinurie-paroxystique-nocturne
2024
false
false
false
France
iptacopan
treatment outcome
insurance, health, reimbursement
paroxysmal nocturnal hemoglobinuria
hemoglobinuria, paroxysmal
adult
guidelines for drug use
administration, oral
complement inactivating agents
orphan drug production
anemia, hemolytic
Iptacopan Hydrochloride
evaluation of the transparency committee
Iptacopan

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/usage-optimal-des-traitements-de-la-covid-19.html
2024
Canada
guidelines for drug use
Trait
Tray Dosing Unit
On Treatment
Treatment
Treat
During Treatment
Treatment Epoch
Optimum
COVID-19
Usage
Biomaterial Treatment
Treatment Study
GDC Treatment Frequency Terminology
Treating
Therapy Object
No Treatment for Diabetes
Tray
COVID-19 Infection

---
https://ansm.sante.fr/tableau-acces-derogatoire/onpattro
2024
false
false
false
France
French
patisiran
drug information
guidelines for drug use
infusions, intravenous
Wild type ATTR amyloidosis
Hereditary ATTR amyloidosis
Cardiac ATTR Amyloidosis
amyloidosis
Transthyretin

---
https://ansm.sante.fr/actualites/difficultes-dapprovisionnement-en-digoxine-nativelle-0-25-mg-hemigoxine-nativelle-0-125-mg-peut-etre-dispense-en-remplacement-a-condition-dadapter-la-posologie
2024
false
false
false
France
French
guidelines for drug use
digoxin
digoxin
drug substitution

---
https://pgtm.qc.ca/wp-content/uploads/2024/05/243103_re_therapie-genique_pgtm_vf-090424.pdf
2024
Canada
guidelines for drug use
acquaintance
Preparation
Gene Therapy
genetic therapy
diethylstilbestrol preparation
Desmosine
knowledge
pharmacies
gene therapy
therapy, nos
Pharmacy
Institution
quebec
insight, nos

---
https://www.has-sante.fr/jcms/p_3519815/fr/primaquine-primaquine-phosphate-paludisme
2024
false
false
false
France
Ovale malaria (disorder)
treatment outcome
insurance, health, reimbursement
recurrence
guidelines for drug use
administration, oral
evaluation of the transparency committee
primaquine phosphate
primaquine
malaria
Vivax Malaria

---
https://ansm.sante.fr/tableau-marr/glibenclamide
2024
false
false
false
France
French
guidelines for drug use
risk management
Drug administration device (physical object)
glyburide
administration, oral
pharmaceutical solutions
hypoglycemic agents
glibenclamide
Device use confusion

---
https://ansm.sante.fr/actualites/decision-du-28-05-2024-fixant-les-regles-auxquelles-se-conforment-les-ersa-pour-effectuer-le-deconditionnement-et-le-reconditionnement-des-specialites-pharmaceutiques-beneficiant-dune-amm-prevue-a-larticle-l-5121-8-du-csp
2024
false
false
false
France
French
guidelines for drug use
guideline
legislation
legislation, pharmacy
Military Health Services
product packaging

---
https://ansm.sante.fr/tableau-acces-derogatoire/fabhalta
2024
false
false
false
France
French
Iptacopan
iptacopan
summary of product characteristics
package leaflet
guidelines for drug use
paroxysmal nocturnal hemoglobinuria
adult
anemia, hemolytic
complement factor B
C3 Glomerulonephritis

---
https://ansm.sante.fr/tableau-marr/velmanase-alfa
2024
false
false
false
France
French
risk management
continuity of patient care
Drug-Related side effects and adverse reactions
guidelines for drug use
velmanase alfa
Velmanase Alfa
infusions, intravenous
enzyme replacement therapy
drug hypersensitivity
home infusion therapy
medication errors
Velmanase Alfa
anaphylaxis
Infusion-Related Reaction

---
https://ansm.sante.fr/uploads/2024/04/30/20240430-rs-mitoxantrone-lettre-pds.pdf
2024
false
false
false
France
French
drug information
guidelines for drug use
mitoxantrone
medication errors

---
https://ansm.sante.fr/actualites/progestatifs-et-risque-de-meningiome-renforcement-des-conditions-de-prescription-et-de-delivrance-de-depo-provera-150-mg-3-ml-et-colprone-5-mg
2024
false
false
false
France
French
guidelines for drug use
meningioma
risk management
legislation, drug
medroxyprogesterone acetate
Drug-Related side effects and adverse reactions
medrogestone
progesterone congeners
medrogestone
medroxyprogesterone

---
https://ansm.sante.fr/informations-de-securite/nouvelles-conditions-de-prescription-et-de-delivrance-des-specialites-a-base-dacetate-de-medroxyprogesterone-depo-provera-150-mg-3-ml-et-de-medrogestone-colprone-5-mg-liees-au-risque-de-meningiome-a-compter-du-1er-juillet-2024
2024
false
false
false
France
French
guidelines for drug use
meningioma
risk management
legislation, drug
medroxyprogesterone acetate
Drug-Related side effects and adverse reactions
medrogestone
progesterone congeners
medrogestone
medroxyprogesterone
drug prescriptions
Renewal of prescription (procedure)
professional role
physicians
pharmacists
summary of product characteristics
package leaflet

---
https://ansm.sante.fr/tableau-marr/adrenaline-1
2024
false
false
false
France
French
epinephrine
risk management
guidelines for drug use
patients guideline
emergency treatment
Epinephrine autoinjector (physical object)
injections, intramuscular
self administration
video recording

---
https://ansm.sante.fr/actualites/conduites-a-tenir-dans-un-contexte-mondial-de-fortes-tensions-en-pegasys-peginterferon-alfa-2a
2024
false
false
false
France
French
drug information
guidelines for drug use
peginterferon alfa-2a
peginterferon alfa-2a
peginterferon alfa-2a
onco-hematology
Ropeginterferon Alfa-2B

---
https://ansm.sante.fr/tableau-marr/vaccin-contre-le-cholera-vivant-recombine-oral
2024
false
false
false
France
French
cholera vaccines
risk management
administration, oral
cholera
cholera, live attenuated
patients guideline
guidelines for drug use
medication errors

---
https://ansm.sante.fr/tableau-marr/exagamglogene-autotemcel-1
2024
false
false
false
France
French
guidelines for drug use
patients guideline
risk management
exagamglogene autotemcel
Exagamglogene Autotemcel
continuity of patient care

---
https://ansm.sante.fr/tableau-marr/paracetamol-iv
2024
false
false
false
France
French
acetaminophen
infusions, intravenous
administration, intravenous
-
guidelines for drug use
clinical tool
Wrong dose
medication errors

---
https://ansm.sante.fr/tableau-marr/paracetamol-iv-1
2024
false
false
false
France
French
acetaminophen
infusions, intravenous
administration, intravenous
guidelines for drug use
clinical tool
Wrong dose
medication errors

---
https://ansm.sante.fr/tableau-marr/paracetamol-iv-2
2024
false
false
false
France
French
acetaminophen
infusions, intravenous
administration, intravenous
guidelines for drug use
clinical tool
Wrong dose
medication errors

---
https://www.has-sante.fr/jcms/p_3536249/fr/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
package leaflet
summary of product characteristics
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Antineoplastic Agents, Immunological
idecabtagene vicleucel
Multiple myeloma progression
guidelines for drug use
evaluation of the transparency committee
multiple myeloma
idecabtagene vicleucel

---
https://www.has-sante.fr/jcms/p_3534145/fr/menveo-vaccin-meningococcique-des-groupes-a-c-w-135-et-y-conjugue-a-la-proteine-crm197-de-la-toxine-de-corynebacterium-diphteriae-vaccin-anti-meningococcique
2024
false
false
false
France
insurance, health, reimbursement
vaccine potency
meningococcal infections
vaccination
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
injections, intramuscular
Invasive meningococcal disease (disorder)
vaccines, conjugate
Meningococcal Conjugate Vaccine MCV4
guidelines for drug use
evaluation of the transparency committee
vaccination
meningococcal vaccines

---
https://ansm.sante.fr/informations-de-securite/crayon-au-nitrate-dargent-restriction-des-indications-et-rappel-des-risques
2024
false
false
false
France
French
guidelines for drug use
pharmacovigilance note
silver nitrate
silver nitrate
risk

---
https://ansm.sante.fr/tableau-marr/iptacopan
2024
false
false
false
France
French
guidelines for drug use
risk management
patients guideline
Iptacopan
iptacopan

---
https://www.cbip.be/fr/articles/4399?folia=4395
2024
false
false
false
Belgium
French
journal article
belgium
patient education as topic
guidelines for drug use
asthma
pulmonary disease, chronic obstructive
diabetes mellitus
benzodiazepines

---
https://ansm.sante.fr/tableau-marr/trastuzumab-deruxtecan
2024
false
false
false
France
French
risk management
trastuzumab deruxtecan
trastuzumab deruxtecan
infusions, intravenous
Antineoplastic Agents, Immunological
medication errors
guidelines for drug use
lung diseases
patient education handout
patients guideline
trastuzumab deruxtecan
Antineoplastic Agents, Immunological

---
https://ansm.sante.fr/tableau-marr/tebentafusp
2024
false
false
false
France
French
patients guideline
guidelines for drug use
drug information
risk management
tebentafusp
tebentafusp
infusions, intravenous
Cytokine Release Syndrome
signs and symptoms
antineoplastic agents

---
https://ansm.sante.fr/actualites/tramadol-et-codeine-devront-etre-prescrits-sur-une-ordonnance-securisee-des-le-1er-decembre
https://ansm.sante.fr/actualites/decision-du-24-09-2024-portant-application-dune-partie-de-la-reglementation-des-stupefiants-et-fixant-des-durees-de-prescription-tramadol-codeine
2024
false
false
false
France
French
patients guideline
guidelines for drug use
tramadol
codeine
drug prescriptions
legislation, pharmacy
prescription drug diversion
prescription drug misuse
opioid-related disorders
risk
risk management
analgesics, opioid
dihydrocodeine
Duration of Therapy

---
https://ansm.sante.fr/tableau-acces-derogatoire/beremagene-geperpavec
2024
false
false
false
France
French
Beremagene Geperpavec
beremagene geperpavec
summary of product characteristics
package leaflet
guidelines for drug use
genetic therapy
gene therapy
biological products
epidermolysis bullosa dystrophica
infant
child
adolescent
adult
wounds
mutation
COL7A1 Gene Mutation

---
https://www.has-sante.fr/jcms/p_3545107/fr/yorvipath-palopegteriparatide-hypoparathyroidie-chronique
2024
false
false
false
France
Palopegteriparatide
palopegteriparatide
chronic disease
adult
treatment outcome
insurance, health, reimbursement
guidelines for drug use
Product containing only recombinant parathyroid hormone in parenteral dose form (medicinal product form)
orphan drug production
hormone replacement therapy
Recombinant parathyroid hormone (substance)
evaluation of the transparency committee
hypoparathyroidism

---
https://ansm.sante.fr/tableau-acces-derogatoire/qarziba
https://ansm.sante.fr/actualites/decision-du-30-09-2024-etablissant-un-cpc-du-medicament-qarziba-dinutuximab-beta-4-5-mg-ml-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
neuroblastoma
infant
child
guidelines for drug use
dinutuximab beta
dinutuximab
antineoplastic combined chemotherapy protocols
High Risk Neuroblastoma

---
https://ansm.sante.fr/informations-de-securite/caspofungine-lansm-recommande-de-ne-pas-utiliser-de-membrane-derivee-du-polyacrylonitrile-chez-les-patients-en-soins-intensifs-sous-hemofiltration
2024
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
Caspofungin
risk management
intensive care
hemofiltration
Lack of drug action (finding)
Hemofiltration system (physical object)
physicochemical incompatibility
polyacrylonitrile

---
https://ansm.sante.fr/tableau-acces-derogatoire/blincyto
2024
false
false
false
France
French
insurance, health, reimbursement
blinatumomab
Consolidation Therapy
guidelines for drug use
summary of product characteristics
package leaflet
blinatumomab
infusions, intravenous
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
precursor b-cell lymphoblastic leukemia-lymphoma
Measurable Residual Disease Negativity

---
https://ansm.sante.fr/informations-de-securite/oxbryta-voxelotor-suspension-de-lautorisation-de-mise-sur-le-marche-de-lunion-europeenne
https://ansm.sante.fr/actualites/oxbryta-voxelotor-conduite-a-tenir-suite-a-la-suspension-de-lautorisation-de-mise-sur-le-marche
2024
false
false
false
France
French
Safety-Based drug withdrawals
voxelotor
pharmacovigilance note
voxelotor
guidelines for drug use
drugs, investigational
france
europe
hematologic agents
Vaso-Occlusive Crisis

---
https://ansm.sante.fr/tableau-marr/etrasimod
2024
false
false
false
France
French
risk management
administration, oral
etrasimod
continuity of patient care
guidelines for drug use
patient education handout
pregnancy
patients guideline
Upfront Treatment
Drug Exposure
etrasimod
Etrasimod Arginine

---
https://www.cbip.be/fr/articles/4411?folia=4409
2024
false
false
false
Belgium
French
journal article
guidelines for drug use
belgium
anti-bacterial agents
ambulatory care
anti-infective agents

---
https://ansm.sante.fr/tableau-acces-derogatoire/jemperli
2024
false
false
false
France
French
summary of product characteristics
package leaflet
dostarlimab
guidelines for drug use
antineoplastic agents
infusions, intravenous
antineoplastic combined chemotherapy protocols
carboplatin
paclitaxel
Carboplatin/Dostarlimab/Paclitaxel Regimen
adult
endometrial neoplasms
Recurrent Endometrial Carcinoma
Advanced Endometrial Carcinoma

---
https://pgtm.qc.ca/wp-content/uploads/2024/10/20241008_pgtm_rapport-ketamine-crps-fibromyalgie.pdf
2024
Canada
guidelines for drug use
ketamine
fibromyalgia
multifactorial inheritance
fibromyositis, nos
complex regional pain syndromes
pain, nos
lumen of vein

---
https://ansm.sante.fr/actualites/clarithromycine-recommandations-de-bon-usage-pour-contribuer-a-garantir-la-couverture-des-besoins-des-patients
2024
false
false
false
France
French
guidelines for drug use
clarithromycin
anti-bacterial agents
anti-bacterial agents
clarithromycin
clarithromycin
patients guideline
guideline

---
https://www.has-sante.fr/jcms/p_3554673/fr/nexviadyme-avalglucosidase-alfa-maladie-de-pompe
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Avalglucosidase Alfa
avalglucosidase alfa
enzyme replacement therapy
guidelines for drug use
evaluation of the transparency committee
glycogen storage disease type ii

---